載入...
Drug–drug interactions during antiviral therapy for chronic hepatitis C
The emergence of direct-acting antiviral agents (DAAs) for HCV infection represents a major advance in treatment. The NS3 protease inhibitors, boceprevir and telaprevir, were the first DAAs to receive regulatory approval. When combined with PEG-IFN and ribavirin, these agents increase rates of susta...
Na minha lista:
| 發表在: | Nat Rev Gastroenterol Hepatol |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
2013
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4634866/ https://ncbi.nlm.nih.gov/pubmed/23817323 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrgastro.2013.106 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|